Genetic Variants and Alzheimer's Disease Biomarkers
Author Information
Author(s): Kauwe John S. K., Cruchaga Carlos, Karch Celeste M., Sadler Brooke, Lee Mo, Mayo Kevin, Latu Wayne, Su'a Manti, Fagan Anne M., Holtzman David M., Morris John C., Goate Alison M.
Primary Institution: Washington University School of Medicine
Hypothesis
Are variants in BIN1, CLU, CR1, and PICALM associated with cerebrospinal fluid biomarkers for Alzheimer's disease?
Conclusion
The study found no significant association between the genetic variants and cerebrospinal fluid levels of Aβ42 or ptau181.
Supporting Evidence
- 355 genetic variants were analyzed in over 600 individuals.
- No significant associations were found between the SNPs and CSF biomarker levels.
- The study had adequate power to detect effects as small as a 1.05 fold difference.
- Previous studies suggested additive effects of CLU and APOE on Aβ deposition.
- Findings suggest that genetic variants may not directly alter CSF levels of Aβ42 or ptau181.
Takeaway
The researchers looked for links between certain genes and Alzheimer's disease markers in the brain but didn't find any strong connections.
Methodology
The study involved genotyping 355 variants in over 600 individuals and analyzing their cerebrospinal fluid biomarker levels.
Limitations
The study may not detect rare variations or complex interactions that could influence biomarker levels.
Participant Demographics
The sample included 407 individuals from Washington University and 257 from the Alzheimer's Disease Neuroimaging Initiative, with a mix of cases and controls.
Statistical Information
P-Value
p=0.31, p=0.44, p=0.48
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website